Mukhopadhyay S - Search Results

1

Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis.

Banerjee M, Pal R, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Acta Diabetol. 2022 Jun;59(6):783-791. doi: 10.1007/s00592-022-01866-3. Epub 2022 Mar 6. Acta Diabetol. 2022. PMID: 35249140

2

The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults.

Bhadada SK, Chadha M, Sriram U, Pal R, Paul TV, Khadgawat R, Joshi A, Bansal B, Kapoor N, Aggarwal A, Garg MK, Tandon N, Gupta S, Kotwal N, Mahadevan S, Mukhopadhyay S, Mukherjee S, Kukreja SC, Rao SD, Mithal A. Bhadada SK, et al. Among authors: mukhopadhyay s. Arch Osteoporos. 2021 Jun 26;16(1):102. doi: 10.1007/s11657-021-00954-1. Arch Osteoporos. 2021. PMID: 34176015

3

Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence.

Pal R, Joshi A, Bhadada SK, Banerjee M, Vaikkakara S, Mukhopadhyay S. Pal R, et al. Among authors: mukhopadhyay s. Endocr Pract. 2022 Apr;28(4):425-432. doi: 10.1016/j.eprac.2022.02.003. Epub 2022 Feb 11. Endocr Pract. 2022. PMID: 35158058 Free PMC article. Review.

4

Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.

Banerjee M, Maisnam I, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Cardiovasc Drugs Ther. 2024 Aug;38(4):739-746. doi: 10.1007/s10557-023-07432-5. Epub 2023 Jan 25. Cardiovasc Drugs Ther. 2024. PMID: 36696050

5

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Banerjee M, Pal R, Mukhopadhyay S, Nair K. Banerjee M, et al. Among authors: mukhopadhyay s. J Clin Endocrinol Metab. 2023 Jun 16;108(7):1806-1812. doi: 10.1210/clinem/dgad076. J Clin Endocrinol Metab. 2023. PMID: 36800286

6

SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.

Banerjee M, Pal R, Nair K, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Indian Heart J. 2023 Mar-Apr;75(2):122-127. doi: 10.1016/j.ihj.2023.03.003. Epub 2023 Mar 11. Indian Heart J. 2023. PMID: 36914068 Free PMC article.

7

Gout.

Banerjee M, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. N Engl J Med. 2023 Mar 30;388(13):e47. doi: 10.1056/NEJMc2216467. N Engl J Med. 2023. PMID: 36988610 No abstract available.

8

Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.

Banerjee M, Pal R, Maisnam I, Chowdhury S, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Diabetes Obes Metab. 2023 Sep;25(9):2697-2703. doi: 10.1111/dom.15157. Epub 2023 Jun 19. Diabetes Obes Metab. 2023. PMID: 37334516

9

Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.

Banerjee M, Maisnam I, Pal R, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. Eur Heart J. 2023 Oct 1;44(37):3686-3696. doi: 10.1093/eurheartj/ehad522. Eur Heart J. 2023. PMID: 37605637

10

Letter to Editor From Banerjee et al: "Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure".

Banerjee M, Maisnam I, Mukhopadhyay S. Banerjee M, et al. Among authors: mukhopadhyay s. J Clin Endocrinol Metab. 2024 Jan 18;109(2):e873-e874. doi: 10.1210/clinem/dgad506. J Clin Endocrinol Metab. 2024. PMID: 37623277 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,705 results

Search Page

Filters